Update in PET Imaging of Nonsmall Cell Lung Cancer

Seminars in Nuclear Medicine

Volumn 34, Issue 2, 2004, Pages 134-153

  Rohren, Eric M ^a   Lowe, Val J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; HUMAN; IMAGING SYSTEM; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 1642275571     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2003.12.004     Document Type: Article

References (60)

1. Cancer Facts and Figures 2003, in American Cancer Society, Surveillance Research. Atlanta, American Cancer Society, 2003
2. Swensen SJ, Jett JR, Hartman TE, et al: Lung cancer screening with CT: Mayo Clinic experience. Radiology 226:756-761, 2003
3. Garg K, Keith RL, Byers T, et al: Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results. Radiology 225:506-510, 2002
4. Erasmus JJ, Connolly JE, McAdams HP, et al: Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 20:43-58, 2000
5. Kubota K, Matsuzawa T, Fujiwara T, et al: Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 31:1927-1932, 1990
6. Duhaylongsod FG, Lowe VJ, Patz EJ, et al: Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110:130-139, 1995
7. Bury T, Dowlati A, Paulus P, et al: Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Resp J 9:410-414, 1996
8. Knight SB, Delbeke D, Stewart JR, et al: Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 109:982-988, 1996
9. Gupta NC, Maloof J, Gunel E: Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943-948, 1996
10. Lowe VJ, Duhaylongsod FG, Patz EF, et al: Pulmonary abnormalities and PET data analysis: A retrospective study. Radiology 202:435-439, 1997
11. Lowe VJ, Fletcher JW, Gobar L, et al: Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16:1075-1084, 1998
12. Croft DR, Trapp J, Kernstine K, et al: FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 36:297-301, 2002
13. Goo JM, Im JG, Do KH, et al: Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology 216:117-121, 2000
14. Wilkinson MD, Fulham MJ, McCaughan BC, et al: Invasive aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography. Clin Nucl Med 28:234-235, 2003
15. Lewis PJ, Salama A: Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nuc Med 35:1647-1649, 1994
16. Yap CS, Schiepers C, Fishbein MC, et al: FDG-PET imaging in lung cancer: how sensitive is it for bronchoalveolar carcinoma? Eur J Nucl Med Mol Im 29:1166-1173, 2002
17. Erasmus JJ, McAdams HP, Patz EF Jr, et al: Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 170:1369-1373, 1998
18. Swensen SJ, Viggiano RW, Midthun DE, et al: Lung nodule enhancement at CT: multicenter study. Radiology 214:73-80, 2000
19. Tateishi U, Nishihara H, Tsukamoto E, et al: Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comp Assist Tomogr 26:185-190, 2002
20. Brown RS, Leung JY, Kison PV, et al: Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40:556-565, 1999
21. Marom EM, Aloia TA, Moore MB, et al: Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33:99-107, 2001
22. Nathan MA, Mullan BP, Hartman TECharacterization of the solitary pulmonary nodule 18F-FDG PET versus nodule enhancement CTEur J Nucl Med30Suppl 22003S151
23. Marom EM, Sarvis S, Herndon JE, et al: T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 223:453-459, 2002
24. Zhuang H, Pourdehnad M, Lambright ES, et al: Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412-1417, 2001
25. Matthies A, Hickeson M, Cuchiara A, et al: Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871-875, 2002
26. Demura Y, Tsuchida T, Ishizaki et al: 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 44:540-548, 2003
27. Erasmus JJ, McAdams HP, Rossi SE, et al: FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 175:245-249, 2000
28. Gupta NC, Rogers JS, Graeber GM, et al: Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 122:1918-1924, 2002
29. Murray JG, Erasmus JJ, Bahtiarian EA, et al: Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:359-360, 1997
30. Van Schil PE, Van HRH, Schoofs EL: The value of mediastinoscopy in preoperative staging of bronchogenic carcinoma. J Thorac Cardiovasc Surg 97:240-244, 1989
31. Patterson GA, Ginsberg RJ, Poon PY, et al: A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 94:679-684, 1987
32. Wahl RL, Quint LE, Greenough RL, et al: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191:371-377, 1994
33. Patz EJ, Lowe VJ, Goodman PC, et al: Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 108:1617-1621, 1995
34. Scott WJ, Schwabe JL, Gupta NC, et al: Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 58:698-703, 1994
35. Sasaki M, Ichiya Y, Kuwabara Y, et al: The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography. Eur J Nucl Med 23:741-747, 1996
36. Steinert HC, Hauser M, Allemann F, et al: Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 202:441-446, 1997
37. Sazon DA, Santiago SM, Soo HG, et al: Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Resp Critical Care Med 153:417-421, 1996
38. Valk PE, Pounds TR, Hopkins DM, et al: Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 60:1573-1581, 1995
39. Vansteenkiste JF, Mortelmans LA: FDG-PET in the locoregional lymph node staging of non-small cell lung cancer: a comprehensive review of the leuven lung cancer group experience. Clin Pos Imaging 2:223-231, 1999
40. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
41. Lardinois D, Weder W, Hany T, et al: Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003
42. Griffeth LK, Rich KM, Dehdashti F, et al: Brain metastases from non-central nervous system tumors: Evaluation with PET. Radiology 186:37-44, 1993
43. Palm I, Hellwig D, Leutz M, et al: Brain metastases of lung cancer: Diagnostic accuracy of positron emission tomography with fluorodeoxyglucose (FDG-PET). Med Klin 94:224-227, 1999
44. Rohren EM, Provenzale JM, Barboriak DP, et al: Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 226:181-187, 2003
45. Boland GW, Goldberg MA, Lee MJ, et al: Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194:131-134, 1995
46. Erasmus JJ, Patz EJ, McAdams HP, et al: Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:1357-1360, 1997
47. Bury T, Barreto A, Daenen F, et al: Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244-1247, 1998
48. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212:803-809, 1999
49. Bury T, Dowlati A, Paulus P, et al: Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 10:2529-2534, 1997
50. Lewis P, Griffin S, Marsden P, et al: Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265-1266, 1994
51. Frank A, Lefkowitz D, Jaeger S, et al: Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Rad Oncol Biol Phys 32:1495-1512, 1995
52. Lowe VJ, Hebert ME, Hawk TC, et al: Chest wall FDG accumulation in serial FDG-PET images in patients being treated for bronchogenic carcinoma with radiation. J Nucl Med 35:76P, 1994
53. Mah K, Cladwell CB, Ung YC, et al: The impact of (18)F-FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Rad Oncol Biol Phys 52:339-350, 2002
54. Erdi YE, Rosenzweig K, Erdi AK, et al: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiotherapy Oncol 62:51-60, 2002
55. Jeong HJ, Min JJ, Park JM, et al: Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nuc Med Commun 23:865-870, 2002
56. Ahuja V, Coleman RE, Herndon J, et al: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918-924, 1998
57. Dhital K, Saunders CA, Seed PT, et al: [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18:425-428, 2000
58. Vesselle H, Grierson J, Muzi M, et al: In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315-3323, 2002
59. Yasukawa T, Yoshikawa K, Aoyagi H, et al: Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 41:283-290, 2000
60. Hustinx R, Lemaire C, Jerusalem G, et al: Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 44:533-539, 2003